- Home
- WKC vs KARD Comparison
WKC vs KARD Comparison
Compare WKC & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | WKC | KARD |
|---|---|---|
| Founded | 1984 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil Refining/Marketing | |
| Sector | Energy | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.9B |
| IPO Year | 1994 | 2026 |
Fundamental Metrics
Financial Performance| Metric | WKC | KARD |
|---|---|---|
| Price | $35.40 | $20.85 |
| Analyst Decision | Hold | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $28.00 | N/A |
| AVG Volume (30 Days) | ★ 838.5K | 226.5K |
| Earning Date | 04-23-2026 | N/A |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.44 | N/A |
| Revenue | ★ $36,916,600,000.00 | N/A |
| Revenue This Year | $0.62 | N/A |
| Revenue Next Year | $3.42 | N/A |
| P/E Ratio | $24.33 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $22.21 | $19.41 |
| 52 Week High | $41.20 | $27.00 |
Technical Indicators
Market Signals| Indicator | WKC | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 48.93 |
| Support Level | $22.77 | $19.67 |
| Resistance Level | $37.88 | $22.64 |
| Average True Range (ATR) | 0.87 | 1.41 |
| MACD | -0.18 | 0.06 |
| Stochastic Oscillator | 10.53 | 38.12 |
Price Performance
Historical ComparisonAbout WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. It earns the majority of its revenue from the Aviation segment.
About KARD Kardigan Inc. Common Stock
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.